279 related articles for article (PubMed ID: 21802008)
1. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.
Miduturu CV; Deng X; Kwiatkowski N; Yang W; Brault L; Filippakopoulos P; Chung E; Yang Q; Schwaller J; Knapp S; King RW; Lee JD; Herrgard S; Zarrinkar P; Gray NS
Chem Biol; 2011 Jul; 18(7):868-79. PubMed ID: 21802008
[TBL] [Abstract][Full Text] [Related]
2. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
3. Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases.
Dao VH; Ourliac-Garnier I; Logé C; McCarthy FO; Bach S; da Silva TG; Denevault-Sabourin C; Thiéfaine J; Baratte B; Robert T; Gouilleux F; Brachet-Botineau M; Bazin MA; Marchand P
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770981
[TBL] [Abstract][Full Text] [Related]
4. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.
Deng X; Elkins JM; Zhang J; Yang Q; Erazo T; Gomez N; Choi HG; Wang J; Dzamko N; Lee JD; Sim T; Kim N; Alessi DR; Lizcano JM; Knapp S; Gray NS
Eur J Med Chem; 2013; 70():758-67. PubMed ID: 24239623
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases.
Dakin LA; Block MH; Chen H; Code E; Dowling JE; Feng X; Ferguson AD; Green I; Hird AW; Howard T; Keeton EK; Lamb ML; Lyne PD; Pollard H; Read J; Wu AJ; Zhang T; Zheng X
Bioorg Med Chem Lett; 2012 Jul; 22(14):4599-604. PubMed ID: 22727640
[TBL] [Abstract][Full Text] [Related]
7. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.
Moreau P; Dezhenkova LG; Anizon F; Nauton L; Thery V; Liang S; Kaluzhny DN; Shtil AA
Anticancer Agents Med Chem; 2014; 14(9):1228-36. PubMed ID: 25175798
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
[TBL] [Abstract][Full Text] [Related]
9. Discovery of N-substituted 7-azaindoles as PIM1 kinase inhibitors - Part I.
Barberis C; Moorcroft N; Arendt C; Levit M; Moreno-Mazza S; Batchelor J; Mechin I; Majid T
Bioorg Med Chem Lett; 2017 Oct; 27(20):4730-4734. PubMed ID: 28947155
[TBL] [Abstract][Full Text] [Related]
10. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.
Xia Z; Knaak C; Ma J; Beharry ZM; McInnes C; Wang W; Kraft AS; Smith CD
J Med Chem; 2009 Jan; 52(1):74-86. PubMed ID: 19072652
[TBL] [Abstract][Full Text] [Related]
12. Scaffold-focused virtual screening: prospective application to the discovery of TTK inhibitors.
Langdon SR; Westwood IM; van Montfort RL; Brown N; Blagg J
J Chem Inf Model; 2013 May; 53(5):1100-12. PubMed ID: 23672464
[TBL] [Abstract][Full Text] [Related]
13. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
[TBL] [Abstract][Full Text] [Related]
14. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
[TBL] [Abstract][Full Text] [Related]
15. Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.
Quevedo CE; Bataille CJR; Byrne S; Durbin M; Elkins J; Guillermo A; Jones AM; Knapp S; Nadali A; Walker RG; Wilkinson IVL; Wynne GM; Davies SG; Russell AJ
Bioorg Med Chem; 2020 Nov; 28(22):115724. PubMed ID: 33128909
[TBL] [Abstract][Full Text] [Related]
16. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
[TBL] [Abstract][Full Text] [Related]
17. Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
Rothweiler U; Eriksson J; Stensen W; Leeson F; Engh RA; Svendsen JS
Eur J Med Chem; 2015 Apr; 94():140-8. PubMed ID: 25768698
[TBL] [Abstract][Full Text] [Related]
18. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A.
Sarno S; Mazzorana M; Traynor R; Ruzzene M; Cozza G; Pagano MA; Meggio F; Zagotto G; Battistutta R; Pinna LA
Cell Mol Life Sci; 2012 Feb; 69(3):449-60. PubMed ID: 21720886
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and activities of new indolopyrrolobenzodiazepine derivatives toward acute myeloid leukemia cells.
Giraud F; Bourhis M; Ebrahimi E; Herfindal L; Choudhury RR; Bjørnstad R; Døskeland SO; Anizon F; Moreau P
Bioorg Med Chem; 2015 Nov; 23(22):7313-23. PubMed ID: 26526744
[TBL] [Abstract][Full Text] [Related]
20. Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
More KN; Hong VS; Lee A; Park J; Kim S; Lee J
Bioorg Med Chem Lett; 2018 Aug; 28(14):2513-2517. PubMed ID: 29871845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]